Date	Event	Description
24 April 2012	New citation required and conclusions have changed	The addition of new evidence to this review has changed the results relating to pneumonia.
11 November 2011	New search has been performed	New literature search run. Four new included studies added. Two of these (Anzueto 2009; Ferguson 2008 total 1579 participants) added twice daily 250 µg fluticasone to salmeterol. The other two new studies (Rennard 2009; Tashkin 2008 total 2355 participants) added twice daily 160 µg or 320 µg budesonide to formoterol.
23 March 2010	Feedback has been incorporated	Comment from Aaron Tejani and Nicole Bruchet added
22 July 2008	Amended	Review converted to RevMan 5
22 January 2008	Amended	Following the identification an error in the data analysis we have revised the odds ratio for pneumonia. The data were incorrectly entered in the formoterol arm from the study by Calverley 2003. This amendment changed the pooled OR for all studies from 1.62 (95% CI 1.35 to 1.94) to OR 1.58; (95% CI 1.32 to 1.88). This does not alter the conclusions of the review.
22 August 2007	New citation required and conclusions have changed	This review contains evidence from 5 studies previously included in a review of combination therapy in COPD (Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long‐acting beta‐agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2004, Issue 3), with new data from four studies (Kardos 2007; O'Donnell 2006; SCO100470; TORCH). New findings There was no significant difference in the odds of death between combination therapy and LABA. Exacerbation rates are lower with combination therapy over LABA. Pneumonia was more frequent with combination therapy than with LABA. Additional work should focus on budesonide and formoterol, and the collection of confirmatory evidence on the frequency of pneumonia.